Avadel Pharmaceuticals (AVDL) Change in Accured Expenses (2016 - 2022)
Historic Change in Accured Expenses for Avadel Pharmaceuticals (AVDL) over the last 8 years, with Q4 2022 value amounting to -$4.0 million.
- Avadel Pharmaceuticals' Change in Accured Expenses fell 16539.97% to -$4.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $227000.0, marking a year-over-year decrease of 7463.69%. This contributed to the annual value of $16.4 million for FY2024, which is 277.05% down from last year.
- Per Avadel Pharmaceuticals' latest filing, its Change in Accured Expenses stood at -$4.0 million for Q4 2022, which was down 16539.97% from $1.7 million recorded in Q3 2022.
- Avadel Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $3.3 million during Q2 2021, with a 5-year trough of -$6.6 million in Q4 2020.
- Over the past 5 years, Avadel Pharmaceuticals' median Change in Accured Expenses value was -$640500.0 (recorded in 2021), while the average stood at -$1.1 million.
- Per our database at Business Quant, Avadel Pharmaceuticals' Change in Accured Expenses crashed by 34126.46% in 2020 and then soared by 33487.54% in 2021.
- Avadel Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $1.0 million in 2018, then soared by 168.24% to $2.7 million in 2019, then plummeted by 341.26% to -$6.6 million in 2020, then surged by 76.88% to -$1.5 million in 2021, then crashed by 165.4% to -$4.0 million in 2022.
- Its Change in Accured Expenses was -$4.0 million in Q4 2022, compared to $1.7 million in Q3 2022 and $245000.0 in Q2 2022.